A naukri.com initiative
Bioengineer
3d
364
Image Credit: Bioengineer
Histotripsy Activates Immune Response to Target Cancer Cells Beyond the Liver
- Histotripsy, a non-invasive ultrasound-based therapy, has gained traction at the University of Michigan Health system for liver tumor treatment.
- Developed by biomedical engineers at the University of Michigan, histotripsy uses ultrasound waves to fragment tumor tissues without traditional methods' side effects.
- Researchers are studying histotripsy's immunological responses beyond liver cancers to treat melanoma and pancreatic cancer effectively.
- Histotripsy reduces tumor hypoxia, which inhibits immune cells' function, by creating an immunosuppressive microenvironment in tumors.
- The therapy triggers immunological events, such as recruitment and activation of cytotoxic T cells, contributing to anti-tumor immune responses.
- Histotripsy shows potential as a local and systemic cancer therapy by enhancing immune responses and improving clinical outcomes.
- Combining tumor ablation with immune modulation, histotripsy complements treatments like chemotherapy and radiation for enhanced efficacy.
- Ongoing research investigates histotripsy's ability to alter immune cell populations and create biomarkers for personalized treatment planning.
- Histotripsy's liberation of tumor-associated antigens and reversal of hypoxia enhance systemic anti-tumor immunity to prevent metastasis.
- Collaborative efforts at the University of Michigan explore histotripsy's potential in multimodal cancer therapy to improve patient outcomes and quality of life.
Read Full Article
21 Likes
For uninterrupted reading, download the app